HMGCR and sarcopenia: Taken together, these findings revealed no significant genetic associations for lowering LDL and no associations for the drug targets HMGCR and NPC1L1, suggesting that observational associations between higher LDL and sarcopenia risk may have been biased due to residual confounding.